|
GluN2C/D-selective Antagonists for Treatment of Neurological Disorders
Application
A new series of compounds for selectively inhibiting N-methyl-D-aspartate (NMDA) receptor subunits for the treatment of Parkinson's disease, schizophrenia, treatment-resistant depression, and ischemia.
Key Benefits
Improved anatomical selectivity in NMDA receptor modulation may result in fewer adverse side effects.
Targeted antagonism...
Published: 4/23/2024
Contributor(s): Timothy Acker, Stephen Traynelis, Dennis Liotta
|